Medison Pharma Enters into an Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo (cemiplimab) Globally for Cancer Treatment
Shots:
- Medison & Regeneron will jointly commercialize Libtayo in selected European markets & additional markets globally for indications incl. cutaneous squamous cell carcinoma, advanced basal cell carcinoma, NSCLC & cervical cancer
- As per the agreement, the companies will jointly collaborate with all stakeholders & regulatory authorities to transfer the commercialization activities for Libtayo to Medison during H1’24. Earlier in Jul 2022, Regeneron acquired the exclusive worldwide, development, commercialization & manufacturing rights for Libtayo from Sanofi
- Libtayo is a fully human mAb that functions by targeting the immune checkpoint inhibitor receptor PD-1 on T cells, developed using Regeneron's VelocImmune technology
Ref: Medison Pharma | Image: Medison Pharma
Related News:- Regeneron Reports Positive Results of Odronextamab in P-II (ELM-2) Trial for the Treatment of Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
